Postmarketing Surveillance Study of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
- Registration Number
- NCT02238171
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
To obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 346
Inclusion Criteria
- Patients of both gender, older than 40 years, who suffer from chronic obstructive Pulmonary disease
- Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
Exclusion Criteria
• Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® Inhalets
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Chronic Obstructive Pulmonary Disease Atrovent® inhalets -
- Primary Outcome Measures
Name Time Method Investigator assessment of improvement of the clinical picture rated on a 6-point symptom profile Up to 4 weeks after first drug administration
- Secondary Outcome Measures
Name Time Method Assessment of efficacy by investigator on a 4-point scale Up to 4 weeks after first drug administration Number of patients with adverse drug reactions Up to 4 weeks after first drug administration Assessment of efficacy by patient on a 4-point scale Up to 4 weeks after first drug administration Assessment of tolerability by investigator on a 4-point scale Up to 4 weeks after first drug administration Assessment of tolerability by patient on a 4-point scale Up to 4 weeks after first drug administration